We work with partners worldwide across the continuum of healthcare to co-create unique solutions for diabetes management that support patient healing – and bring progress to life
Diabetes Management
Diabetes Management
Diabetes is a chronic condition, with no known cure, that affects people from every walk of life, in every region around the globe. The direct and indirect costs of Diabetes are staggering, totaling $760 Billion globally1.
1. Rodriguez-Saldana, J. (2023). The Economic Costs of Diabetes. In: The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-031-25519-9_3
15+ Years
Of experience in the diabetes market.
1 Second
Every second a patient receives a medical device containing a dsm-firmenich biomedical solution.
10 Million
Proven performance - supporting 10 million Continuous Glucose Monitors (CGM) annually.
Application spotlight: Glycemic control - with no limitations
Sparsa is a next-generation biomaterial platform developed by our experts to bring new levels of performance to glucose-limiting membranes.
This unique, amphiphilic polyurethane enables both oxygen and glucose to diffuse through the bio-sensors - and deliver fast, accurate readings using a single material. The result is greater efficiency and sustainability for our partners – with less materials required and no need for polymer multi-blends.
It’s good news for patients too. Sparsa is not just limited to monitoring glucose. It can also be used to deliver accurate readings for various other analytes throughout the day – thus enabling diabetes sufferers to manage their health even more reliably.
Unmet needs in the market
The vascular biomedical diabetes treatment market faces a significant need for advanced materials in the design and manufacturing of continuous glucose monitors (CGMs) that offer enhanced tunability.
Biomedical's innovation
Our TPU medical-grade biomaterials can be customized to avoid the need for blending in hydrophilic materials, allowing them to be coated onto biosensors with greater manufacturing efficiency, increased consistency, and improved sustainability compared to traditional multiblends approaches2.
2. Data on file at Biomedical
Discover our integrated biomaterial portfolio for diabetes management
CGM sensors
Our partners draw on our portfolio of medical polyurethanes (including Sparsa, Carbosil® and Pursil®) to create glucose-limiting membranes for CGM sensors that contribute to improved diabetes management for patients.
Beta cell therapy
As the diabetes market continues to explore new methods for insulin delivery, one potential answer lies in our drug delivery solutions. These biocompatible materials enable controlled, sustained release over long periods of time - with the potential for less frequent dosing and increased therapy adherence.
Emerging cell therapies
Next-generation solutions (for example, artificial pancreas) need to perform safely inside the human body, long-term. Here, our portfolio of natural biomaterials and medical polyurethanes can provide an effective biological scaffold.
Insulin pumps
Our medical polyurethanes can even be used for the tubing component used in insulin pumps. Their biocompatibility makes them ideal for this frequent body-contact application.
Technical resources
Looking for more information on how our biomaterial solutions for diabetes can help you tackle unmet needs?
How Membranes Allow Oxygen-Dependent Sensors to Function Longer and More Accurately
Carbosil® Brochure
Pursil® Brochure
TheraPEA™ Brochure
Our diabetes team is here and ready to support you
Discover how our team can partner with you to co-create new diabetes management solutions that can improve patient care.
-
-
Get In Touch
-
Expert Services
-
Products
-
Customized Solutions